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Abstract
Malaria rapid diagnostic tests (RDTs) are instrument-free tests that provide results within 20 min and can be used by community health
workers. RDTs detect antigens produced by the Plasmodium parasite such as Plasmodium falciparum histidine-rich protein-2 (PfHPR2) and
Plasmodium lactate dehydrogenase (pLDH). The accuracy of RDTs for the diagnosis of uncomplicated P. falciparum infection is equal or
superior to routine microscopy (but inferior to expert microscopy). Sensitivity for Plasmodium vivax is 75–100%; for Plasmodium ovale and
Plasmodium malariae, diagnostic performance is poor. Design limitations of RDTs include poor sensitivity at low parasite densities,
susceptibility to the prozone effect (PfHRP2-detecting RDTs), false-negative results due to PfHRP2 deﬁciency in the case of pfhrp2 gene
deletions (PfHRP2-detecting RDTs), cross-reactions between Plasmodium antigens and detection antibodies, false-positive results by other
infections and susceptibility to heat and humidity. End-user’s errors relate to safety, procedure (delayed reading, incorrect sample and buffer
volumes) and interpretation (not recognizing invalid test results, disregarding faint test lines). Withholding antimalarial treatment in the case
of negative RDT results tends to be infrequent and tendencies towards over-prescription of antibiotics have been noted. Numerous
shortcomings in RDT kits’ labelling, instructions for use (correctness and readability) and contents have been observed. The World Health
Organization and partners actively address quality assurance of RDTs by comparative testing of RDTs, inspections of manufacturing sites, lot
testing and training tools but no formal external quality assessment programme of end-user performance exists. Elimination of malaria
requires RDTs with lower detection limits, for which nucleic acid ampliﬁcation tests are under development.
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Malaria in the Endemic setting: Geography
and Disease Burden
Malaria is endemic in 106 countries and accounted for 655 000
deaths in 2010, 86% of which occurred among children [1].
Plasmodium falciparum (the most lethal species) is by far the
predominant species in tropical regions. Plasmodium vivax
(tolerant to lower ambient temperatures still facilitating
replication in the vector) is mainly found in South-America
and Asia (where it co-occurs with P. falciparum), as well as in
the horn of Africa [2]. Plasmodium ovale is mainly restricted to
sub-Saharan Africa while Plasmodium malariae is present in
most malaria endemic regions. Plasmodium knowlesi infections
are frequently encountered in Malaysian Borneo [3] and have
also been observed in other south-east Asian countries [4,5].
Infected patients develop fever and non-speciﬁc symptoms
(‘uncomplicated malaria’), which, in the case of P. falciparum
infection in vulnerable patients, can quickly progress to vital
organ dysfunction with coma, pulmonary oedema or shock
(‘severe malaria’). Severe malaria cases have also been
described for P. vivax infections [6]. On the other hand there
is asymptomatic malaria (i.e. the presence of malaria parasites
without malaria symptoms), occurring in up to 90% of
individuals in endemic settings [7], but also seen in low
transmission areas [8,9].
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Prompt and accurate diagnosis of malaria is needed to
prevent progress to severe malaria. Due to the non-speciﬁc
symptoms, clinical diagnosis leads to over-diagnosis and over-
treatment [10–12]. Therefore, the World Health Organization
(WHO) recommends parasitological conﬁrmation of malaria
before commencing treatment [13]. This recommendation,
referred to as the ‘Test and Treat’ policy, has recently been
amended with a recommendation for improved surveillance
(‘3T’, Test, Treat, Track), including active case detection in
high-risk populations in malaria elimination settings (http://
www.who.int/malaria/test_treat_track/en/index.html).
Scope of the Present Review
The present review addresses the strengths and limitations of
RDTs employed for diagnosis of patients suspected of having
malaria in endemic settings. It focuses on RDTs currently
available to and performed by (community) health workers in
remote ﬁeld settings. For issues of selection, procurement and
deployment of RDTs, we refer to documents issued by WHO
[2] (http://www.who.int/malaria/en/) and the Foundation of
Innovative Diagnostics (FIND) (http://www.ﬁnddiagnostics.org/
programs/malaria-afs/).
Malaria Rapid Diagnostic Tests: Mechanism,
Target Antigens and Formats
RDTs are easy-to-use hand-held tests that provide results
within 20 min. They detect Plasmodium antigens by an antigen-
antibody reaction on a nitrocellulose strip. For P. falciparum
detection, the target antigens are histidine-rich protein-2
(PfHPR2) and P. falciparum-speciﬁc Plasmodium lactate dehy-
drogenase (Pf-pLDH). The P. vivax-pLDH antigen is speciﬁc for
P. vivax and pan-pLDH and aldolase are antigens common to all
human Plasmodium species. Different RDT formats detecting
different combinations of target antigens are available (Table 1,
Fig. 1). For a detailed explanation of the RDT mechanism we
refer to another paper in this issue (Maltha et al., Malaria rapid
diagnostic tests in travel medicine).
Microscopy and Malaria RDTs in the
Endemic Setting
If available, light microscopy is still the primary method of
malaria diagnosis in endemic settings [14]: Giemsa-stained
thick blood ﬁlm analysis is cheap and enables scoring of
parasite density, to identify the different Plasmodium species
and to differentiate sexual (gametocytes) from asexual stages.
However, microscopy is labour-intensive and its quality in
endemic settings is often inadequate due to problems with
electricity, microscopes and stains and because of shortage of
competent staff [15–20].
Malaria RDTs overcome many of the limitations of micros-
copy. They are designed as instrument-free tests that can be
used by community health workers [21]. The Test and Treat
policy has fuelled deployment of RDTs (WHO, http://www.
who.int/malaria/test_treat_track/en/index.html). The number
of malaria RDTs used in the public sector of endemic countries
has increased from <200 000 in 2005 to 88 000 000 in 2010,
and an annual need for 1.5 billion RDTs has been forecasted
(http://www.rollbackmalaria.org/index.html). The increased
demand for malaria RDTs has led to an increased supply, with
currently more than 200 RDT products and 60 manufacturers
worldwide [2].
What are the Diagnostic Characteristics of
Malaria RDTs in the Endemic Setting?
A recent Cochrane meta-analysis compiled diagnostic accuracy
for 74 studies assessing accuracy of RDTs for diagnosis of
Plasmodium species targeted
(number of recommended RDTs) Antigens targeted
Two-band
RDTa
Three-band
RDTa
P falciparum (n = 21) PfHRP2 19
PfHRP2 & Pf-pLDH 1b 1C
P falciparum and the four common
human Plasmodium species (n = 8)
PfHRP2 & pan-pLDH 7
Pf-pLDH & pan-pLDH 1
PfHRP2 & Aldolase 0
P falciparum and P vivax (n = 4) PfHRP2 & Pv-pLDH 4
Pf-pLDH & Pv-pLDH 0d
P vivax (n = 1) Pv-pLDH 1
PfHRP2, Plasmodium falciparum histidine-rich protein 2; Pf-pLDH, Plasmodium falciparum-speciﬁc parasite lactate
dehydrogenase; pan-pLDH, pan-Plasmodium pLDH; Pv-pLDH, Plasmodium vivax-speciﬁc pLDH.
aTwo-band RDTs consist of a control line and a test line directed to one antigen, three-band tests contain two test lines
each directed to a different target antigen.
bTwo-band RDT targeting both PfHRP2 & Pf-pLDH at the same test line.
cThree-band RDT combining PfHRP2 and Pf-pLDH detection.
dNot available as commercial RDT format.
TABLE 1. Different antigens used in
malaria RDTs and number of RDT
products included in the list of RDT
products recommended by the Glo-
bal Fund to Fight AIDS, Tuberculosis
and Malaria (Version6) www.theglob
alfund.org/Documents/psm/PSM_QA
Diagnostics_Malaria_list/
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uncomplicated P. falciparum malaria in endemic settings
[22,23]. PfHRP2-detecting RDTs displayed a slightly higher
sensitivity compared with Pf-pLDH-detecting RDTs (95.0% vs.
93.2%, p = 0.34), at the trade-off of a lower speciﬁcity (95.2%
vs. 98.5%, p = 0.01). The lower speciﬁcity of PfHRP2-detecting
RDTs can partly be explained by the slow clearance of PfHRP2:
in patients with recently treated or self-cleared infections
PfHRP2 may persist in the blood for several weeks [24,25] and
still be present during a new episode of fever. For P. vivax
diagnosis, reported sensitivities for pan-pLDH, Pv-pLDH and
aldolase-detecting RDTs are, respectively, 76.1–100.0% [26–
37], 76.9–100.0% [33,34,38–42] and 80.0–81.4% [37,43]. A
prospective ﬁeld study in Peru, comparing side-to-side 11 RDT
products, revealed high sensitivity (>99.0%) for 9/11 products
with no difference between pan-pLDH vs. Pv-pLDH detection
[33]. RDT sensitivity for P. ovale and P. malariae detection in
endemic settings has hardly been assessed due to their low
prevalence, but reports in travel medicine show poor results
(sensitivity range 5.5–86.7% and 21.4–45.2%, respectively; see
Maltha et al., Malaria rapid diagnostic tests in travel medicine,
in this issue). For all species, RDT sensitivity declines at lower
parasite density [34,44,45].
There is much heterogeneity among reported results for
RDT diagnostic accuracy, which may depend on several
factors: the RDT product used [45–47], local epidemiology
of malaria, the reference method used (microscopy vs. PCR),
the particular end-user (e.g. experienced laboratory worker
vs. community health worker) and available infrastructure.
It must be taken into account that correctly identifying the
presence of malaria parasites does not imply the patient is ill
due to malaria [48]. Especially in severe disease, bacterial (co-)
infections may be overlooked [49–51].
Moreover, only a few studies assessed operational param-
eters such as proportion of invalid tests and proportion of test
lines with faint intensity [33,34,52] and most ﬁeld studies
assessed the accuracy of RDTs per se rather than during
routine unsupervised use. Finally, although RDT performance
for the detection of P. falciparum in endemic settings has been
shown to be equal or superior to routine microscopy [53,54],
they are not as accurate as expert microscopy and do not
generate all information provided by microscopy. Therefore,
where established, microscopy should not be neglected for
training and quality assurance.
Limitations of Malaria RDTs Related to
Design and Engineering
RDTs have inherent limitations. As mentioned above, low
parasite densities (which may cause clinical disease in vulner-
able patients [55]) are frequently missed. Samples with high
parasite densities are vulnerable to the prozone effect (i.e.
false-negative test results or test lines of low line intensity due
to antigen excess). Prozone affects PfHRP2-detecting but not
Pf-pLDH-detecting RDTs [52,56] and its occurrence depends
on RDT product and lot [52].
False-negative results for PfHRP2-detecting RDTs have also
been noted in P. falciparum strains lacking the pfhrp2 gene, which
may account for 25.7–41.0% of P. falciparum samples in the
Peruvian Amazon [33,57]. A recent study from Mali retrospec-
tively assessed more than 10-year-old ﬁlter paper samples of
P. falciparum blood that tested negative by PfHRP2-detecting
RDTs and observed negative pfhrp2 gene ampliﬁcation results
[58], but in view of methodological issues these ﬁndings await
conﬁrmation. In addition, extensive diversity in the pfhrp2 gene
both within and between countries has been reported, but no
correlation with RDT performance was demonstrated [59]. A
recent study assessing P. falciparum isolates from India did,
however, ﬁnd differences in the detection limit of a PfHRP2-
detecting RDT for different PfHRP2 antigens [60], which,
however, may also be explained by variable levels of PfHRP2
production between P. falciparum strains [61], resulting in
different PfHRP2 concentrations at identical parasite densities.
RDTs do not include wash steps, making them vulnerable to
false-positive results because of non-speciﬁc bindings. Cross-
reactions between Plasmodium species and target antigens are
observed for P. falciparum and P. vivax: in a ﬁeld study in Peru,
up to 2.5% of P. vivax samples showed visible Pf-pLDH or
PfHRP2 test lines for 10/12 different products tested [33].
Likewise, P. falciparum samples at high parasite densities may
cross-react with the Pv-pLDH line (up to 29.1% of samples in
6/9 Pv-pLDH RDTs tested [62]). False-positive reactions have
FIG 1. Different platforms of RDTs From left to right: dipstick (to be
dipped in a tube), cassette, hybrid and cardboard. Cassettes are the
easiest to use and are the most common platform (UNITAID, http://
www.theglobalfund.org/en/innovativeﬁnancing/unitaid/).
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been attributed to several immunological and infectious factors
such as the rheumatoid factor, hepatitis C, schistosomiasis,
toxoplasmosis, dengue, leishmaniasis, Chagas disease and
human African Trypanosomiasis [45,63–66].
Finally, extreme temperatures and humidity affect the
performance of RDTs [55,67]. Some RDT products withstand
temperatures up to 40°C, but most RDTs (e.g. 32/40 (80%)
products assessed in a previous study at our centre [68]) are
labelled to be stable up to 30°C, which is easily exceeded in
tropical settings. Pf-pLDH-detecting RDTs have been reported
to be less heat resistant although some Pf-pLDH-detecting
RDTs actually have extended temperature stabilities [45,67].
Limitations of Malaria RDTs Related to End-
user’s Performance
Table 2 lists the most frequent errors committed by end-users
in remote settings; they include critical steps related to safety
and accuracy of procedure and interpretation. Reading beyond
the recommended reading time proves to be a persistent
error: at warm ambient temperatures, the excess sample with
unbound conjugate ﬂows back by capillary action of the
sample/buffer pad and gets passively deposited on the test
band, thereby generating a false-positive line, a so-called
‘Backﬂow’ phenomenon [69].
Most errors by end-users can be explained by shortcomings
in packaging, labelling, correctness and readability of instruc-
tions [68,70], and unsatisfactory comprehension of ‘universal’
ISO15223-based graphical symbols [71]. In addition, short-
comings in other contents of RDT kits may add to poor
performance, such as desiccants with absent or difﬁcult to
assess humidity indicator [72], tiny alcohol swabs [70], pipette
transfer devices with no volume mark and incorrectly pack-
aged lancets (Figs 2 and 3). A combination of (repeat) training,
clear and simple bench-site job aids (in local language) and
supervision visits are effectively and sustainably contributing to
correct end-user’s performance [21,73,74].
Acceptability of RDTs and Adherence to
RDT Test Results
The implementation of an RDT may evoke conﬂicting
responses from the health worker (who may feel a loss of
credibility when making a clinical diagnosis of malaria) and the
patient (who insists on treatment irrespective of the RDT
result) [70]. Further, withholding malaria treatment in the case
of a negative RDT result in non-severe disease has been
reported to occur infrequently in some studies [75–79] but
frequently in others [80,81]. Adherence to RDT results
appeared to be safe [81,82] although an improved strategy
for both positive (possibility of bacterial co-infection) [50,83]
and negative RDT results is needed. High frequencies of
antibiotic prescription in cases of negative RDT results have
been observed [80,84]. Repeat testing in the case of negative
RDT results may be useful in a developing infection when
antigen concentrations are still too low to be detected. For all
other causes of false-negative results that are mentioned above,
repeat testing is of no use. Because of antigen persistency,
especially PfHRP2 as described above, RDTs cannot be used for
treatment follow-up (see also ‘Malaria rapid diagnostic tests in
travel medicine’, which can be found in this edition).
Further, although the Test and Treat policy has proven to
be safe and efﬁcacious in uncomplicated malaria [80,82,85,86],
there is still debate about its universal application [87]. In
particular, a positive RDT result can indicate an asymptomatic
carrier who is suffering from non-malaria illness but the results
may prevent the clinician from exploring other febrile diseases
[88] and therefore antibiotics may be withheld from those who
need them. This is of concern as bacterial infections, especially
invasive salmonellosis, are observed to occur together or
shortly after P. falciparum infections [50,89].
How to Assure Quality of RDTs in Endemic
Settings?
Substandard malaria RDTs are widespread in resource-limited
settings [90,91] and lot-to-lot variations may affect perfor-
mance of RDTs [92]. Regulatory approvals from high-income
countries are of limited help: for instance, the requirements for
the European Union’s conformity label (CE Mark) in the case of
malaria RDTs are purely administrative [90]. To overcome this
vacuum, WHO and partners organized the ‘Prequaliﬁcation of
Diagnostics Programme’: in addition to RDT product dossier
assessments, manufacturing sites are inspected for compliance
with ISO13485 standards and an active post-marketing surveil-
lance system has been installed (http://www.who.int/diagnos-
tics_laboratory/evaluations/en/). Further, the so-called WHO/
FIND Rounds assess RDTs also for diagnostic accuracy
(P. falciparum and P. vivax) and heat stability (http://www.
ﬁnddiagnostics.org/programs/malaria-afs/malaria/rdt_quality_
control/product_testing/) and WHO/FIND further offer a lot
testing programme. As to transport and storage, the develop-
ment and local production of evaporative power-free cooling
boxes in Cambodia and Afghanistan is of note [34,93].
At the site of performance, few tools for QC of individual
RDT test kits are available. WHO/FIND produce job aids and
appropriate training materials (http://www.ﬁnddiagnostics.org/
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programs/malaria-afs/) and have developed positive controls
(freeze dried recombinant parasite antigen) that are currently
under implementation and evaluation. Pending this, there are
no controls at the bench except for cross-checking with
microscopy [94]. It should further be noted that appearance of
the control line is not a guarantee for correct test perfor-
mance: it only testiﬁes to correct migration of the signal
antibody-antigen complex but does not control for other
errors such as application of insufﬁcient volume of sample or
for use of an incorrect diluent [95].
TABLE 2. Errors committed by RDT end-users in malaria endemic settings. Study subjects were village or community health
workers (Cambodia, Lao PDR, Mali, The Philippines and Zambia), staff of peripheral health centres (Malawi, Sudan and Uganda)
and hospital laboratory staff (Mozambique and DR Congo). All subjects had been trained in RDT use and performance
Errors ranked according to
chronology of test procedure Effects/Comments Countries References
Not checking expiration date of
the device
Confusion may arise from the
way of displaying the expiry
date [70]
Lao PDR,
The Philippines, Uganda, Zambia
[21,70,73,74]
Not checking the humidity indicator
of the desiccant
Humidity weakens the bonds
between antibodies and
nitrocellulose strip and delays
particle re-solubilization [72]
Laos PDR,
The Philippines, Zambia
[73,74]
Not using gloves Gloves protect from
blood-borne infection
Zambia [21,73]
Reusing the same gloves for
different patients
Uganda,
Zambia
[21,70]
Not identifying the cassette with
the patients’ name or laboratory number
Risk of inversion of results
between patients
Zambia [21,73]
Not cleaning/disinfecting the ﬁnger
before pricking
Lao PDR,
The Philippines, Uganda,
Zambia
[21,70,73,74]
Not allowing the ﬁnger to dry after
cleaning and before pricking
Antiseptic needs enough action time Lao PDR,
The Philippines, Zambia
[21,73,74]
Reusing a lancet for a next patient Zambia [21]
Desterilizing the lancet before use
(by touching the bench or hands)
Zambia [21]
Pricking the wrong place on the
ﬁnger (palmar instead of lateral side)
Pricking the palmar side of the
ﬁnger is more painful than
pricking at the side
Zambia [21]
Not throwing the lancet in a sharps
container
Zambia [21,73]
Dispensing the wrong volume of
blood or not completely transferring
the blood to the sample well
(leaving blood on the wall of the well)
1 Insufﬁcient volume of blood may
cause false-negative results
2 Too much blood may increase the
risk or the intensity of a prozone
effect [56]
3 Too much blood will cause
decreased clearance of the strip
Malawi,
Sudan,
Uganda,
Zambia
[21,70,73,106,107]
Distributing blood into the buffer well
and/or buffer into the sample well
Sample and buffer well are not
always unequivocally labelled [68]
Laos PDR,
The Philippines
[74]
Substituting the buffer by another
liquid (e.g. distilled water)
Use of any other liquid than the
buffer provided in the RDT’s
kit may cause false-positive
results [95]
Mali, Mozambique [108]
Dispensing the wrong volume
of buffer
1 Insufﬁcient volume of buffer
will impede clearance of the strip
and/or slow down migration with
failure to generate a control line
(invalid test results) [109]
2 Too high volume of buffer may
cause false-positive results due
to non-speciﬁc bindings
Lao PDR,
Sudan,
The Philippines, Uganda,
Zambia
[21,70,73,74,106]
Not using a levelled surface to
place the cassette
Decreasing of the migration time
may cause false-negative results[110]
DR Congo,
Lao PDR, Sudan,
The Philippines, Zambia
[21,74,106]
Not discarding the used materials correctly Lao PDR,
The Philippines, Zambia
[21,73,74]
Not respecting the correct reading time 1 Reading too early may cause
false-negative results
2 Reading too late may cause
false-positive results due to a
backﬂow phenomenon [111]
Lao PDR, Malawi, Sudan,
The Philippines, Uganda,
Zambia
[21,70,73,74,106,107]
Disregarding faint or weak test lines
as negative
Faint test lines may be difﬁcult to see,
particularly in unfavourable light
conditions (night shifts) and by
elderly readers [55,70]
DR Congoa,
Lao PDR,
The Philippines, Zambia
[21,73,74]
Not recognizing invalid test results DR Congoa, Zambia [73]
Interpreting line intensities as indicative
of disease severity (and installing
treatment accordingly)
Line intensity is not related to severity Lao PDR,
The Philippines, Uganda,
[70,74]
Not interpreting correctly a
three- band RDT
Difﬁculties in deﬁning the species
involved based on the test line results
DR Congoa, Sudan [106]
aPierre Mukadi et al., Challenges in Malaria Research: Progress Towards Elimination, Switzerland, 10–12 October 2012.
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Special Situations and Future Directions for
Malaria RDTs
P. falciparum malaria in pregnancy is a potentially life-threat-
ening infection associated with miscarriage and low birth
weight [96]. Infected erythrocytes attach to the placental
capillaries, resulting in very low parasite densities in the
peripheral blood. Microscopy fails to detect many cases of
malaria infection in pregnancy [97]. As plasma PfHRP2
concentrations reﬂect P. falciparum parasite biomass [98,99],
RDTs may be expected to be useful for malaria diagnosis in
pregnancy. However, although PfHRP2-detecting RDTs per-
form better than peripheral microscopy, many cases are
missed compared with PCR [100,101].
Likewise, changing trends in malaria epidemiology argue for
RDTs with lower detection limits: in some areas, malaria
transmission rates have declined and malaria control is shifting
to the near-elimination phase. Especially in this situation it is
important to also diagnose and treat asymptomatic carriers
(with very low parasite densities), as they are a potential
source of transmission [17,102]. Developments are focusing
on nucleic acid ampliﬁcation-based platforms, which have
detection limits <1 parasite/lL, but these are still awaiting
adaptation to a point-of-care format [102,103].
The decreasing burden of malaria does not imply a
reduction in the numbers of RDTs used (as illness due to
malaria still needs to be conﬁrmed or excluded) but the
proportion of non-malaria febrile illnesses such as dengue,
respiratory tract infections, invasive salmonellosis and others is
likely to increase (FIND, http://www.ﬁnddiagnostics.org/pro-
grams/malaria-afs/about-afs/). As most malaria endemic set-
tings are resource poor, affordable diagnostic tests for such
infections are highly needed. Fulﬁllment of this need is
expected to consolidate acceptance and implementation of
malaria RDTs by end-users [70,104] .
Conclusion
Malaria RDTs are increasingly used in endemic settings and ﬁt
into the WHO ‘Test and Treat’ strategy. For the diagnosis of
uncomplicated P. falciparum infection, their diagnostic sensitiv-
ity is equal or superior to routine microscopy. RDTs are
subject to limitations related to design and production, as well
as end-user performance, many of which can easily be
prevented or remediated. Active efforts by WHO can
contribute to quality assurance of RDTs along the chain of
production to the bench.
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FIG 2. The contents of an RDT kit: sealed pouch (opened for the
photo) containing cassette and desiccant, a (tiny) alcohol swab, lancet,
transfer device and buffer vial. In most cases, only one buffer vial is
supplied, and buffer vials are frequently lost or displaced [68]. The
correct name and intended use of the RDT are not mentioned on the
pouch nor on the cassette; the characters on the buffer label are very
small.
FIG 3. Transfer devices used to transfer capillary or venous blood to
the RDT: pipettes (upper left and right), loop, capillaries, straws and
inverted cup (below and insert). Some capillaries are very small, not
easy to use and have no volume mark. The inverted cup proved to be
the most accurate and safest blood transfer device [105].
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